Search Results
Your search for ,New matches 16912 pages
Showing 8851 - 8900ASCO, ABIM Collaborate on Pathway to Maintenance of Board Certification
ASCO and the American Board of Internal Medicine (ABIM) have announced that they are working to co-create a pathway to provide doctors with a flexible way to maintain board certification. The work with ASCO reflects real progress in ABIM’s efforts to collaborate with medical societies. Beginning in ...
Valued Mentors and a Link Between Science and Medicine Paved the Road to Oncology for Alice Tsang Shaw, MD, PhD
Lung cancer expert Alice Tsang Shaw, MD, PhD, was born and reared in Gaithersburg, a small suburb located to the northwest of Washington, DC. Both her parents were chemists, and during high school, Dr. Shaw had a keen interest in science, particularly biology, yet the thought of pursuing a career...
NIH Completes In-Depth Genomic Analysis of 33 Cancer Types
Researchers funded by the National Institutes of Health (NIH) have completed a detailed genomic analysis, known as the PanCancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer, according to a release issued by the NIH late last...
Education Came First for Breast Cancer Expert Beverly Moy, MD, MPH, Daughter of Chinese Immigrants
Beverly Moy, MD, MPH, grew up in Brooklyn, New York, in a modest working-class home. Both her parents were immigrants from China. “Education is highly prized in Chinese culture, and my home life was no exception. I didn’t speak any English when I began kindergarten, so that was a bit challenging,...
A Love of Science Leads to an Esteemed Career in Cancer Research for Razelle Kurzrock, MD
Razelle Kurzrock, MD, regarded internationally for her work in translational science, was born and reared in Toronto, Canada. “My parents were immigrants from Eastern Europe. My father, who was Jewish, was a Holocaust survivor. My parents put a strong emphasis on education,” she said. ‘The...
New Fellows Selected for ASCO’s 2018-2019 Health Policy Fellowship Program
ASCO recently announced that Trevor Royce, MS, MD, MPH, and Sheetal Kircher, MD, have been selected for the ASCO Health Policy Fellowship Program. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge-base, skills, and experience necessary to...
FDA Oncology Drug Approvals Granted Between June 2017 and May 16, 2018
Over the past year (June 2017–May 2018), the U.S. Food and Drug Administration (FDA) granted approval to a number of new oncology drug products, including several biosimilar products. Here we provide the labeling approved for these novel drugs and new indications. EPOETIN ALFA-EPBX (RETACRIT)...
A Love of Older Patients With Cancer Drives a Career Path for Arti Hurria, MD, FASCO
Arti Hurria, MD, FASCO, who is Director of City of Hope’s Center for Cancer and Aging, is a first generation of immigrant parents from India. “My parents left India and moved from England to Canarsie, Brooklyn, where I was born. When I was 8, my family moved to Southern California, partly due to...
Husband and Wife Leave a Giant Legacy in Oncology
The remarkable careers of Jimmie C. Holland, MD, and James F. Holland, MD, spanned collectively for more than a century, leaving an indelible footprint in oncology clinical care and research. Synonymous with cancer care itself, the Hollands were a living documentary of the rich and dramatic history ...
International Oncologist Nagi S. El Saghir, MD, FACP, Returned Home to Make a Difference in Lebanon and Worldwide
Internationally renowned expert on the early detection, prevention, and treatment of younger women with breast cancer, Nagi S. El Saghir, MD, FACP, FASCO, was born on January 5, 1953, in Bint Jbeil, a village in southern Lebanon. His parents moved to Beirut in 1948, at the height of the...
Pioneering Researcher and Oncologist Volker S. Diehl, MD, Helped Unlock the ‘Black Box’ of Hodgkin Lymphoma
Volker S. Diehl, MD, the internationally renowned hematologist and researcher, was born in Berlin, Germany, on February 28, 1938—arguably one of the most tumultuous periods in world history. Germany had just invaded Austria, signaling the dark intentions of the Third Reich. In 1943, the air raids...
AUA 2018: Is Prostate Cancer Screening and Risk Stratification Moving Beyond the PSA Test?
New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening, were presented at the 113th Annual Meeting of the American Urological Association (AUA). PSA Screening of African American...
AUA 2018: Use of MRI for Prostate Cancer Screening and Management
Use of magnetic resonance imaging (MRI) in the diagnosis of prostate cancer is increasing and brings added value to screening and surveillance, according to new studies presented this year during the 113th Annual Meeting of the American Urological Association (AUA). Four studies highlighting the...
AUA 2018: Panel Discusses New Research on Prostate Cancer Management Protocols and Treatments
Researchers presented new findings on a Korean Food and Drug Administration (KFDA)-approved robotic system, safety of testosterone therapy after prostate cancer, and active surveillance protocol for low-risk prostate cancer patients at the 113th Annual Meeting of the American Urological Association ...
AUA 2018: More Than 40% of Prostate Biopsies May Have Been Avoided With Use of Assay for Detection
A multicenter study that validated the clinical performance of IsoPSA—a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen (PSA)—was presented at the 13th Annual Meeting of the American Urological...
ASCO Launches Its Education Scholars Program
Education is such an integral part of ASCO’s strategic plan to reduce the burden of cancer for all patients, it is incorporated into the Society’s mission statement to “conquer cancer through research, education, and promotion of the highest patient care.” In 2017, ASCO’s Board of Directors voted...
Hormonal Contraception and Breast Cancer Risk
As reported in The New England Journal of Medicine by Lina S. Mørch, PhD, of the University of Copenhagen, and colleagues, a Danish study has shown that the risk of breast cancer is increased in hormonal contraception users vs nonusers, with the absolute increase in risk being small. The study...
Roger Lo, MD, PhD, Receives American Skin Association Award for Skin Cancer Research
THE AMERICAN SKIN ASSOCIATION (ASA) recently announced Roger Lo, MD, PhD, of the David Geffen School of Medicine at the University of California (UCLA), as the recipient of the Abby S. and Howard P. Milstein Innovation Award for Melanoma/Non-Melanoma Skin Cancer Research. The award is available...
AACR Honors Recipients of 2018 Scientific Achievement Awards and Lectureships
THE AMERICAN ASSOCIATION for Cancer Research (AACR) honors the following cancer researchers and clinicians who were recognized for their scientific achievements during the AACR Annual Meeting 2018: Isaiah J. Fidler, DVM, PhD, FAACR, AACR President (1984-1985), Fellow of the AACR Academy and...
American Cancer Society Awards New Research and Training Grants
THE AMERICAN CANCER Society has approved funding for 110 grants totaling $47,624,000 to researchers and health professionals across 72 institutions nationwide in the first of 2 grant cycles for 2018. Of these grants, 101 are new and 9 are renewals of previous grants. Two individuals have been...
Stage IV Lung Cancer Did Not Stop Me From Climbing Mera Peak
A veteran mountain climber and skier, I’ve been healthy for most of my 61 years, so it was especially shocking to experience a bout of shortness of breath during a moderately intense mountain bike ride with my wife, Jan, in the spring of 2014. A never-smoker, I was used to climbing up high mountain ...
Study Finds Mutated Tau May Be a Susceptibility Factor for Cancer
Tau proteins perform the function of stabilizing microtubules, a major element of the eukaryotic cytoskeleton. Traditionally associated with neurodegeneration, tau also has a role in the maintenance of genome stability and chromosome integrity and is tightly linked to the development of cancer. A...
Trametinib Treatment for Histiocytic Sarcoma With an Activating MAP2K1 Mutation
In a letter to the editor in The New England Journal of Medicine, Gounder et al described the successful treatment of a patient with histiocytic sarcoma and an activating MAP2K1 (MEK1) mutation with the MAPK kinase 1 and 2 inhibitor trametinib (Mekinist). As noted by the authors, patients with...
High–Nicotine-Dependent Smokers Less Likely to Quit After Lung Cancer Screening
A new study by Rojewski et al in CHEST investigated the relationships between the degree of nicotine dependence and both the likelihood of successfully quitting smoking and clinical outcomes in a cohort of screened patients. The study found that patients with a higher nicotine dependence...
FDA Identifies Efficacy Issue in Clinical Trials of Pembrolizumab or Atezolizumab as Monotherapy in Urothelial Cancer With Low Expression of PD-L1
On May 18, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with ...
Antoni Ribas, MD, Recognized for Research in Cancer Immunology
Antoni Ribas, MD, Professor of Medicine and Director of the Tumor Immunology Program at the University of California Jonsson Comprehensive Cancer Center, has been awarded the sixth American Association of Cancer Research–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. The award...
Visible Ink Celebrates 10 Years of Live Patient Performances
On April 16, 2018, Memorial Sloan Kettering Cancer Center (MSK) in New York hosted the annual Visible Ink live performances at The Kaye Playhouse at Hunter College. The evening marked the 10th anniversary of the ongoing one-on-one writing program for patients undergoing cancer treatment at MSK....
Stand Up To Cancer Launches Research Team to Detect Precursor Conditions of Multiple Myeloma
Stand Up To Cancer (SU2C) announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma through the early detection of precursor conditions. In the hope of developing therapies to prevent myeloma in high-risk populations, the project...
Logistics of CAR T-Cell Therapy in Real-World Practice
With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially curative options for incurable hematologic malignancies. Its ...
For James Allison, PhD, Perseverance and Hard Science Are Paramount in Cancer Research
For this installment in the Living a Full Life series of articles, guest editor Jame Abraham, MD, interviewed immunology pioneer James Allison, PhD, Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research,...
Focus on the Tennessee Oncology Practice Society
The Tennessee Oncology Practice Society (TOPS) is among the oldest and one of many politically active ASCO State Affiliates. Founded in 1990, the organization has since been a voice for Tennessee’s diverse community of oncology professionals, advocating for patient access to the best available care ...
Treating Insomnia in Cancer Survivors
A Patient-Centered Outcomes Research Institute–supported randomized clinical trial of cancer survivors showed that 8 weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia among cancer survivors, though improvements were greatest among...
Supporting Patients During and After Cancer Treatment: Evidence-Informed Approach to Lifestyle and Behavior Change
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Lorenzo Cohen, PhD, and Alison Jefferies, BA, MEd, summarize research...
New International Translations of NCCN Guidelines for Patients
The National Comprehensive Cancer Network® (NCCN®) has published a newly translated Italian version of the NCCN Guidelines for Patients® for stomach cancer, funded by No Stomach for Cancer. Over the past year, the NCCN Foundation also worked with the Kidney Cancer Association to translate patient...
Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia
Extended next-generation sequencing genomic profiling in acute myeloid leukemia (AML) has revealed remarkable heterogeneity and molecular complexity of the disease and provided critical insights into the genetic mechanisms underpinning of preleukemic and leukemic pathogenesis.1,2 Despite...
PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer
A targeted therapy that has been effective in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers was...
Targeted Sequencing Detection of Molecular Minimal Residual Disease and Prognosis in Acute Myeloid Leukemia
In a study reported in The New England Journal of Medicine, Mojca Jongen-Lavrencic, MD, PhD, of Erasmus MC Cancer Institute, and colleagues found that molecular minimal residual disease identified by next-generation sequencing during complete remission was associated with an increased risk of...
NCCN Names Wui-Jin Koh, MD, New Chief Medical Officer
The National Comprehensive Cancer Network® (NCCN®) has named Wui-Jin Koh, MD, as Senior Vice President, Chief Medical Officer, a newly created position. Dr. Koh will add additional physician representation at NCCN headquarters, which includes Chief Executive Officer Robert W. Carlson, MD. Dr. Koh...
How a Recent Study Heats up the Debate Over Intraperitoneal Chemotherapy in Newly Diagnosed Advanced Ovarian Cancer
Based on pharmacokinetic and preclinical data, there appears to be a biologic advantage to the use of intraperitoneal chemotherapy in treating some malignancies confined to the abdomen. Since most ovarian, fallopian tube, and peritoneal cancers present and recur in the peritoneal cavity, this...
Adding Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery Improves Outcomes in Advanced Ovarian Cancer
In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by Willemien J. van Driel, MD, PhD, of the Netherlands Cancer Institute, and colleagues, the addition of hyperthermic intraperitoneal chemotherapy (aka HIPEC) to interval cytoreductive surgery following neoadjuvant...
A Lifetime of Accomplishments in Oncology Brings Knighthood to Sir Murray F. Brennan, MD, FACS
Sir Murray F. Brennan, MD, FACS, was born on April 2, 1940, in Auckland, New Zealand, which lies on and around an isthmus surrounded by the sparkling azure waters of the Hauraki Gulf. “I was born at the beginning of World War II. Fortunately, my father was too old to be drafted into the army. I...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO AND ASCO’s Conquer Cancer Foundation recognized winners of ASCO’s 2018 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards during the 2018 ASCO Annual Meeting, June 1 to June 4, in Chicago. The recipients of these awards included researchers, patient advocates, and...
Fox Chase Cancer Center Announces 2018 Award Recipients for Translational Clinical Protocol Development
Fox Chase Cancer Center recently announced the awardees of the 2018 translational clinical protocol development based on basic and preclinical research results. Translational research disease groups were created with a multidisciplinary group of clinical and research-based faculty, with a focus on...
New Updates to Common Rule for Researchers
THIS PAST January, the Department of Health and Human Services (HHS), along with more than a dozen other federal agencies, finalized updates to the Common Rule, which protects human participants in biomedical research. This marked the first time that the Common Rule has been updated in nearly 3...
Enhance Your Annual Meeting Experience With Attendee Resources
More than 39,000 oncology professionals will gather in Chicago for the 2018 ASCO Annual Meeting. The theme for this year’s meeting, selected by 2017–2018 ASCO President Bruce E. Johnson, MD, FASCO, sets an exciting tone for the presentation of advances in the field of cancer care. Delivering...
Register Now for the ASCO Research Community Forum 2018 Annual Meeting
Register now to join research colleagues from across the United States at the ASCO Research Community Forum Annual Meeting. The meeting offers physician researchers and research staff from a variety of programs a unique platform to collaborate and develop solutions to common challenges with...
Nancy L. Bartlett, MD, Moved From Engineering to Medicine After a Stint in the ER
Nationally recognized oncologist Nancy L. Bartlett, MD, had an early love for mathematics and a swooning aversion to the sight of blood. “I was born and reared in Kansas City, Missouri and am a Midwesterner at heart. No one in the family was involved in medicine. My mom was an elementary school...
Four Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO18 on Twitter and Instagram to follow and participate in the Annual Meeting conversation in real time. During last year’s Annual Meeting, more than 17,000 health-care professionals, researchers, news outlets, patients, advocates, and other participants sent more than...
A Commitment to Innovation, Gender Equality, and Family Legacy Inspire Endowed Young Investigator Award Gifts for ASCO’s Conquer Cancer Foundation
Individuals, foundations, and corporations continue to fuel the brightest minds in cancer research through lifetime investments in the Conquer Cancer Grants & Awards program. The roster of endowed Young Investigator Awards (YIA) grew by three in 2018, with awards gifted by Thomas G. Roberts,...
Role of MRI in Detection of Clinically Significant Prostate Cancer: ‘Practice-Affirming’ Results From The PRECISION Trial
Simultaneously presented at the 2018 European Association of Urology meeting and published in The New England Journal of Medicine, the PRECISION trial will go down as a landmark study for solidifying the role of magnetic resonance imaging (MRI) in prostate cancer diagnosis.1 This trial provides...
